317 related articles for article (PubMed ID: 21451123)
41. The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy.
Adjei AA
Clin Lung Cancer; 2005 Nov; 7(3):221-3. PubMed ID: 16354319
[TBL] [Abstract][Full Text] [Related]
42. BRAF mutation predicts sensitivity to MEK inhibition.
Solit DB; Garraway LA; Pratilas CA; Sawai A; Getz G; Basso A; Ye Q; Lobo JM; She Y; Osman I; Golub TR; Sebolt-Leopold J; Sellers WR; Rosen N
Nature; 2006 Jan; 439(7074):358-62. PubMed ID: 16273091
[TBL] [Abstract][Full Text] [Related]
43. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
Wee S; Jagani Z; Xiang KX; Loo A; Dorsch M; Yao YM; Sellers WR; Lengauer C; Stegmeier F
Cancer Res; 2009 May; 69(10):4286-93. PubMed ID: 19401449
[TBL] [Abstract][Full Text] [Related]
44. STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
Wang Z; Yin M; Chu P; Lou M
Aging (Albany NY); 2019 Sep; 11(17):7187-7196. PubMed ID: 31484165
[TBL] [Abstract][Full Text] [Related]
45. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors.
Zhang J; Lodish HF
Blood; 2004 Sep; 104(6):1679-87. PubMed ID: 15166036
[TBL] [Abstract][Full Text] [Related]
46. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
Dogan Turacli I; Ozkan AC; Ekmekci A
Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
[TBL] [Abstract][Full Text] [Related]
47. Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.
Paulo JA; McAllister FE; Everley RA; Beausoleil SA; Banks AS; Gygi SP
Proteomics; 2015 Jan; 15(2-3):462-73. PubMed ID: 25195567
[TBL] [Abstract][Full Text] [Related]
48. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
49. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems.
Hennig M; Yip-Schneider MT; Wentz S; Wu H; Hekmatyar SK; Klein P; Bansal N; Schmidt CM
Hepatology; 2010 Apr; 51(4):1218-25. PubMed ID: 20112426
[TBL] [Abstract][Full Text] [Related]
50. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
[TBL] [Abstract][Full Text] [Related]
51. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
52. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
Kuracha MR; Thomas P; Loggie BW; Govindarajan V
PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
[TBL] [Abstract][Full Text] [Related]
53. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
54. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
[No Abstract] [Full Text] [Related]
55. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.
Kiessling MK; Oberholzer PA; Mondal C; Karpova MB; Zipser MC; Lin WM; Girardi M; Macconaill LE; Kehoe SM; Hatton C; French LE; Garraway LA; Polier G; Süss D; Klemke CD; Krammer PH; Gülow K; Dummer R
Blood; 2011 Feb; 117(8):2433-40. PubMed ID: 21209378
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract][Full Text] [Related]
57. Unraveling the interplay between RAS/RAF/MEK/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy.
Huang Y; Zhen Y; Chen Y; Sui S; Zhang L
Biochem Pharmacol; 2023 Nov; 217():115842. PubMed ID: 37802240
[TBL] [Abstract][Full Text] [Related]
58. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.
Williams TM; Flecha AR; Keller P; Ram A; Karnak D; Galbán S; Galbán CJ; Ross BD; Lawrence TS; Rehemtulla A; Sebolt-Leopold J
Mol Cancer Ther; 2012 May; 11(5):1193-202. PubMed ID: 22411900
[TBL] [Abstract][Full Text] [Related]
59. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O; O'Connor CM; Kulesskiy E; Sangodkar J; Aakula A; Izadmehr S; Yetukuri L; Yadav B; Padzik A; Laajala TD; Haapaniemi P; Momeny M; Varila T; Ohlmeyer M; Aittokallio T; Wennerberg K; Narla G; Westermarck J
Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021885
[TBL] [Abstract][Full Text] [Related]
60. Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors.
Lebedev TD; Khabusheva ER; Mareeva SR; Ivanenko KA; Morozov AV; Spirin PV; Rubtsov PM; Snezhkina AV; Kudryavtseva AV; Sorokin MI; Buzdin AA; Prassolov VS
J Biol Chem; 2022 Aug; 298(8):102226. PubMed ID: 35787369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
